Global GLP-1 Analogues Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global GLP-1 Analogues Market Research Report 2024
GLP-1 analogues are a class of medications used in the treatment of type 2 diabetes. They mimic the effects of glucagon-like peptide 1 (GLP-1), which is a hormone produced by the gut that helps regulate blood sugar levels by stimulating insulin secretion and reducing glucagon secretion.
According to Mr Accuracy reports’s new survey, global GLP-1 Analogues market is projected to reach US$ 3985.9 million in 2034, increasing from US$ 2434 million in 2022, with the CAGR of 6.8% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GLP-1 Analogues market research.
Key manufacturers engaged in the GLP-1 Analogues industry include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Jiangsu Hansoh Pharmaceutical and Shanghai Benemae Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GLP-1 Analogues were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GLP-1 Analogues market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Analogues market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Jiangsu Hansoh Pharmaceutical
Shanghai Benemae Pharmaceutical
Segment by Type
Exenatide
Liraglutide
Semaglutide
Dulaglutide
Other
Hospital
Clinic
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GLP-1 Analogues report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global GLP-1 Analogues market is projected to reach US$ 3985.9 million in 2034, increasing from US$ 2434 million in 2022, with the CAGR of 6.8% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GLP-1 Analogues market research.
Key manufacturers engaged in the GLP-1 Analogues industry include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Jiangsu Hansoh Pharmaceutical and Shanghai Benemae Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GLP-1 Analogues were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GLP-1 Analogues market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Analogues market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Jiangsu Hansoh Pharmaceutical
Shanghai Benemae Pharmaceutical
Segment by Type
Exenatide
Liraglutide
Semaglutide
Dulaglutide
Other
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GLP-1 Analogues report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices